An exterior view of a Dollar Tree store at the Buckhorn...

(Paul Weaver/Getty Images)

Dollar Tree sinks on tariff warning despite handily topping Q1 earnings estimates

The discount retailer warned of a profit hit for the current quarter as tariffs take effect.

6/4/25 10:22AM

Dollar Tree shares sank 9% Wednesday morning, leading S&P 500 decliners, after the discount retailer topped Q1 estimates but warned tariff volatility could affect profits.

Adjusted earnings per share came in at $1.26, beating FactSet estimates of $1.21 and the company’s original guidance of $1.10 to $1.25. Revenue hit $4.6 billion, also above expectations and the high end of its forecast range. Comps and net sales were both lifted by a strong Valentine’s Day and Easter.

Execs on the earnings call said the chain added 2.6 million new shoppers during the quarter and saw a 9% jump in customers who visited the store at least three times a month. The gains came as the chain attracted a broader demographic of shoppers and saw strong demand for grab-and-go items like candy, snacks, and drinks, as well as other key discretionary categories.

Still, the stock dipped after Dollar Tree warned EPS could drop by as much as 50% for the current quarter, partly because of rising tariff-related costs. The chain reaffirmed its full-year sales outlook of $18.5 billion to $19.1 billion.

Share of rival Dollar General also fell after the report, though the company’s stock had gotten a big boost on Tuesday from posting a blowout quarter of its own.

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

J. Edward Moreno1h

J. Edward Moreno1h

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

Matt Phillips1h

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.